O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-5.92%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$4.16B
AUM Growth
+$4.16B
(-14%)
Cap. Flow
-$176M
Cap. Flow
% of AUM
-4.24%
Top 10 Holdings %
Top 10 Hldgs %
48.04%
Holding
122
New
11
Increased
15
Reduced
22
Closed
16
Top Buys
| 1 |
Pfizer
PFE
|
$97.6M |
| 2 |
Axsome Therapeutics
AXSM
|
$45.1M |
| 3 |
SION
Sionna Therapeutics, Inc. Common Stock
SION
|
$38.8M |
| 4 |
UnitedHealth
UNH
|
$36.8M |
| 5 |
Tarsus Pharmaceuticals
TARS
|
$33.6M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$117M |
| 2 |
Merck
MRK
|
$82.6M |
| 3 |
Biogen
BIIB
|
$77.9M |
| 4 |
Intuitive Surgical
ISRG
|
$54.8M |
| 5 |
Universal Health Services
UHS
|
$48.3M |
Sector Composition
| 1 | Healthcare | 99.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
| $334M | 7.96% | 2,718,735 | – | – |
|
2
Edgewise Therapeutics
EWTX
$1.51B
| $330M | 7.88% | 15,021,721 | – | – |
|
3
Boston Scientific
BSX
$156B
| $284M | 6.77% | 2,813,200 -347,100 | -11% | -$35M |
|
4
Eli Lilly
LLY
$657B
| $279M | 6.65% | 337,600 | – | – |
|
5
Enliven Therapeutics
ELVN
$1.2B
| $157M | 3.73% | 7,959,538 | – | – |
|
|
6
Intuitive Surgical
ISRG
$170B
| $144M | 3.44% | 291,000 -110,700 | -28% | -$54.8M |
|
7
Stryker
SYK
$150B
| $134M | 3.19% | 359,200 +14,800 | +4% | +$5.51M |
|
8
argenx
ARGX
$43.6B
| $122M | 2.92% | 206,700 +17,000 | +9% | +$10.1M |
|
9
Edwards Lifesciences
EW
$47.8B
| $111M | 2.65% | 1,532,000 +386,698 | +34% | +$28M |
|
|
10
UnitedHealth
UNH
$281B
| $105M | 2.51% | 201,200 +70,300 | +54% | +$36.8M |
|
11
ARS Pharmaceuticals
SPRY
$1.15B
| $104M | 2.49% | 8,288,510 | – | – |
|
12
Neurocrine Biosciences
NBIX
$13.8B
| $103M | 2.46% | 934,640 -3,480 | -0.4% | -$385K |
|
|
13
Pfizer
PFE
$141B
| $97.6M | 2.33% | +3,850,200 | New | +$97.6M |
|
14
Alnylam Pharmaceuticals
ALNY
$58.5B
| $93.5M | 2.23% | 346,100 -69,500 | -17% | -$18.8M |
|
15
Integer Holdings
ITGR
$3.78B
| $78.2M | 1.86% | 662,500 +87,500 | +15% | +$10.3M |
|
16
Vertex Pharmaceuticals
VRTX
$100B
| $77.5M | 1.85% | 159,900 +8,900 | +6% | +$4.31M |
|
17
Natera
NTRA
$23.1B
| $77.4M | 1.84% | 547,000 +134,000 | +32% | +$18.9M |
|
18
Ionis Pharmaceuticals
IONS
$6.79B
| $76.6M | 1.83% | 2,540,136 -277,211 | -10% | -$8.36M |
|
19
Disc Medicine
IRON
$2.07B
| $70.2M | 1.67% | 1,415,020 -370,551 | -21% | -$18.4M |
|
20
Thermo Fisher Scientific
TMO
$186B
| $64.2M | 1.53% | 129,000 +44,600 | +53% | +$22.2M |
|
21
Tenet Healthcare
THC
$16.3B
| $62.5M | 1.49% | 465,000 -327,000 | -41% | -$44M |
|
22
Cytokinetics
CYTK
$4.23B
| $60.7M | 1.45% | 1,509,205 -74,800 | -5% | -$3.01M |
|
23
CG Oncology
CGON
$2.04B
| $60.5M | 1.44% | 2,471,994 +1,040,880 | +73% | +$25.5M |
|
24
ArriVent BioPharma
AVBP
$776M
| $56M | 1.33% | 3,027,328 | – | – |
|
25
Avidity Biosciences
RNA
$5.99B
| $53.5M | 1.28% | 1,812,886 +700,000 | +63% | +$20.7M |
|